Ocular Hypertension Treatment Study 20-Year Follow-up: Coordinating Center Grant

高眼压治疗研究 20 年随访：协调中心拨款

基本信息

批准号：
9316636
负责人：
MAE O GORDON
金额：
$ 84.01万
依托单位：
WASHINGTON UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-07-01 至 2020-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9316636
关键词：
African American Age Archives Biometry Blindness Certification Clinical Cohort Studies Collaborations Consent Data Data Set Directories Doctor of Philosophy Ethics Frequencies Grant Guidelines Health Insurance Portability and Accountability Act Human Resources Incidence Institutional Review Boards Internet Joints Letters Modeling Monitor Ocular Hypertension Ophthalmology Optic Disk Participant Patient Self-Report Patient-Centered Care Patients Performance Phase Physiologic Intraocular Pressure Population Preventive treatment Primary Open Angle Glaucoma Procedures Protocols documentation Public Health Publications Reading Reporting Research Resource Sharing Risk Risk Factors Severities Statistical Data Interpretation Testing Time United States Universities Visual Fields Washington administrative database cohort cost cost effective evidence base follow-up hypertension treatment improved outcome medical schools modifiable risk payment phase 1 study phase 3 study programs public health relevance vision science

项目摘要

DESCRIPTION (provided by applicant): Primary open-angle glaucoma (POAG) is one of the leading causes of blindness in the United States and many other nations and is the leading cause of blindness in African Americans. Elevated intraocular pressure (ocular hypertension or OHT) is a major risk factor for developing POAG and the only modifiable risk factor at present. 4-7% of the United States population above age 40 has OHT. A major public health issue is how to apply the principles of patient- centered care and manage this large group of people in an effective and cost-effective manner. The OHTS carefully followed OHT participants for a median of 13 years. (OHTS Phase 1 and 2) This includes 279 participants who developed POAG during the study, the largest inception cohort of POAG patients ever described. We propose to re-examine all surviving OHTS participants at 20 years or more in 2015-2017 (OHTS Phase 3). We will determine the incidence and severity of POAG in the OHTS cohort and determine the frequency and severity of self-reported functional limitations associated with POAG. We will also develop a 20-year prediction model for stratifying OHT patients by their risk of developing POAG and, among those who developed POAG, a prediction model for the rate of visual field loss. OHTS Phase 3 will allow us to develop evidence-based, 20-year guidelines for the management of patients with OHT. This will aid patients and clinicians to make informed decisions about the appropriate frequency of examinations and tests and the benefit of early, preventative treatment. Informed decisions should improve outcomes, reduce costs and reduce patient and clinician burden.

描述（由申请人提供）：原发性开角型青光眼 (POAG) 是美国和许多其他国家失明的主要原因之一，也是非裔美国人失明的主要原因。）是发生 POAG 的主要风险因素，也是目前 4-7% 的美国 40 岁以上人口患有 OHT 的唯一可改变的风险因素。 OHTS 认真跟踪 OHT 参与者长达 13 年（OHTS 第 1 期和第 2 期），其中包括 279 名在 OHTS 期间出现 POAG 的参与者。这项研究是有史以来规模最大的 POAG 患者初始队列，我们建议在 2015 年至 2017 年期间重新检查所有存活 20 岁或以上的 OHTS 参与者（OHTS 第 3 阶段）。我们还将开发一个 20 年预测模型，根据发生 POAG 的风险对 OHT 患者进行分层。谁开发了 POAG，这是一种 OHTS 第 3 阶段的预测模型，这将使我们能够制定基于证据的 20 年 OHT 患者管理指南，这将帮助患者和倡导者做出明智的决定。适当的检查和测试频率以及早期预防性治疗的好处应该可以改善结果、降低成本并减轻患者和临床医生的负担。